Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.000001 USD | -.--% | -.--% | -99.00% |
2023 | Genocea Biosciences, Inc. Went Out of Business | CI |
2023 | Liquidation Plan Approved for Genocea Biosciences, Inc. | CI |
Financials (USD)
Sales 2020 | 1.36M | Sales 2021 | 1.64M | Capitalization | 66.64M |
---|---|---|---|---|---|
Net income 2020 | -43M | Net income 2021 | -33M | EV / Sales 2020 | 50.8 x |
Net cash position 2020 | 55.9M | Net cash position 2021 | 19.96M | EV / Sales 2021 | 28.4 x |
P/E ratio 2020 |
-2.18
x | P/E ratio 2021 |
-2.4
x | Employees | 74 |
Yield 2020 * |
-
| Yield 2021 |
-
| Free-Float | 100% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Tech/Sci/R&D Officer | 52 | 07-02-28 | |
Girish Aakalu
PRN | Corporate Officer/Principal | - | 18-12-09 |
Members of the board | Title | Age | Since |
---|---|---|---|
Ken Bate
CHM | Chairman | 73 | 14-09-10 |
1st Jan change | Capi. | |
---|---|---|
-99.00% | 58 | |
+22.61% | 46.4B | |
-1.52% | 41.75B | |
+48.83% | 41.37B | |
-3.42% | 29.71B | |
+9.95% | 26.01B | |
-18.85% | 19.52B | |
+28.53% | 12.43B | |
+0.38% | 12.18B | |
-0.27% | 12.13B |
- Stock Market
- Equities
- GNCAQ Stock